Sorafenib in advanced melanoma: a critical role for pharmacokinetics? (Q36117220)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Sorafenib in advanced melanoma: a critical role for pharmacokinetics? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Olivier Mir

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

C Lebbe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

B Billemont

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

B Blanchet

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

N Franck

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M Viguier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Coriat

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M Tod

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M-F Avril

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

F Goldwasser

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

5 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

455-461

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

7 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Mutations in GNA11 in uveal melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

2 October 2017

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.287

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405224

Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22767146

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22767146

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Saturable absorption of sorafenib in patients with solid tumors: a population model

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22767146

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.287

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

22767146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767146%20AND%20SRC:MED&resulttype=core&format=json